

Pfizer (COMIRNATY) JN.1 6 months – 4 years

3 mcg/0.3 mL concentrated suspension for injection multi-dose vial



Pfizer (COMIRNATY) JN.1 5 – 11 years

10 mcg/0.3 mL suspension for injection single-dose vial



Pfizer (COMIRNATY) JN.1

12 years+

30 mcg/0.3 mL

suspension for injection

multi-dose vial

doses Do no

Pfizer (COMIRNATY) JN.1 12 years+

> 30 mcg/0.3 mL suspension for injection single-dose glass prefilled syringes



Pfizer (COMIRNATY) Omicron XBB.1.5

6 months – 4 years 3 mcg/0.2 mL concentrated suspension for injection multi-dose vial



Pfizer (COMIRNATY) Omicron XBB.1.5

5 – 11 years 10 mcg/0.3 mL suspension for injection single-dose vial



Pfizer (COMIRNATY) Omicron XBB.1.5 12 years+

30 mcg/0.3 mL



-					
	I		Ţ		
00	MIRN	ATY	30	meg	
act act	icron Ozina	XB mer	B.1.	5 ina	
Ji.	ard ti	Do me:	00	t alle	

CVAS naming convention	Pfizer (JN.1) 6 months – 4 years (Yellow)	Pfizer (JN.1) 5 – 11 years (Light Blue)	Pfizer (JN.1) 12 years+ (Dark Grey)	Pfizer (JN.1) 12 years+ (PFS)	Pfizer (XBB.1.5) 6 months - 4 years (Maroon)	Pfizer (XBB.1.5) 5 - 11 years (Light Blue)	Pfizer (XBB.1.5) 12 years+ (Grey)
Vaccine type	mRNA (nucleic acid)	mRNA (nucleic acid)	mRNA (nucleic acid)	mRNA (nucleic acid)	mRNA (nucleic acid)	mRNA (nucleic acid)	mRNA (nucleic acid)
Approved age	6 months – 4 years	5 – 11 years	12 years and older	12 years and older	6 months to 4 years	5 to 11 years	12 years and older
Dose volume	0.3 mL	0.3 mL	0.3 mL	0.3mL	0.2 mL	0.3 mL	0.3 mL
Doses per vial	3	1	6	1	10	1	6
Dilution required	Yes (1.1 mL)	No	No	No	Yes (2.2 mL)	No	No
ULT freezer storage time	18 months (shelf life) at -90°C to -60°C	18 months (shelf life) at -90°C to -60°C	18 months (shelf life) at -90°C to -60°C	NA	24 months (shelf life) at -90°C to -60°C	24 months (shelf life) at -90°C to -60°C	24 months (shelf life) at -90°C to -60°C
Freezer storage time (unopened)	DO NOT STORE at -25°C to -15°C	DO NOT STORE at -25°C to -15°C	DO NOT STORE at -25°C to -15°C	DO NOT FREEZE	DO NOT STORE at -25°C to -15°C	DO NOT STORE at -25°C to -15°C	DO NOT STORE at -25°C to -15°C
Refrigeration storage time (unopened) ¹	70 days (+2°C to +8°C) within the 18-month shelf life	70 days (+2°C to +8°C) within the 18-month shelf life	70 days (+2°C to +8°C) within the 18-month shelf life	Expiry date printed on the carton and syringe label	70 days (+2°C to +8°C) within the 24-month shelf life	70 days (+2°C to +8°C) within the 24-month shelf life	70 days (+2°C to +8°C) within the 24-month shelf life
Room temperature storage time (unopened)	24 hours pre- and post- dilution (up to +30°C)	24 hours pre- and post-initial puncture (up to +30°C)	24 hours pre- and post-initial puncture (up to +30°C)	12 hours (up to +30°C)	24 hours pre- and post- dilution (up to +30°C)	24 hours pre- and post-initial puncture (up to +30°C)	24 hours pre- and post-initial puncture (up to +30°C)
Storing opened vials	6 hours (up to +30°C)	6 hours (up to +30°C)	6 hours (up to +30°C)	NA	6 hours (up to +30°C)	6 hours (up to +30°C)	6 hours (up to +30°C)
Storing pre-drawn doses	1 hour (up to +30°C) or 6 hours (+2°C to +8°C)	1 hour (up to +30°C) or 6 hours (+2°C to +8°C)	1 hour (up to +30°C) or 6 hours (+2°C to +8°C)	NA	1 hour (up to +30°C) or 6 hours (+2°C to +8°C)	1 hour (up to +30°C) or 6 hours (+2°C to +8°C)	1 hour (up to +30°C) or 6 hours (+2°C to +8°C)
TGA Product Information (PI) and Consumer Medicine Information (CMI)	PI CMI	PI CMI	PI CMI	PI CMI	PI CMI	PI CMI	PI CMI

Notes:

For the latest information on COVID-19 primary course and additional doses advise, please refer to the Australian Immunisation Handbook:

- All adults aged 18 years and over are recommended a single primary dose. Children and adolescents aged under 18 years are not routinely recommended a primary dose.
- People with severe immunocompromise conditions, who are over 6 months of age or older are recommended 2 primary doses and are eligible for a 3rd primary dose based on an individual risk-benefit assessment.
- Infants, children and adolescents aged 6 months to <18 years with conditions other than severe immunocompromise that may increase the risk of severe COVID-19 are eligible for primary dose(s) based on a risk benefit assessment.

If vaccines are stored or handled outside the conditions listed, complete the Cold Chain Breach (CCB) reporting form and email it to the Vaccine Operations Centre (VOC) COVID19VaccineOperationsCentre@health.gov.au.

It is mandatory under the Australian Immunisation Register Act 2015 for vaccination providers to report all vaccinations administrators.

Images © 2024 Pfizer Inc. All rights reserved.